2027 Medicare Advantage star ratings turn contracts into bonus cliffs
CMS rated 508 MA-PD contracts for 2027, and half-star moves on single large contracts repriced 2028 bonus payments, bid strategy and provider network leverage within hours of the release.
The 2027 Medicare Advantage star ratings landed on Oct. 8, 2026, one week before open enrollment, and the market read them in hours rather than weeks. CMS rated 508 MA-PD contracts with an enrollment-weighted average overall rating of 3.99, down slightly from 4.01 for 2026. The headline number was unremarkable. What happened underneath it was not: single-contract half-star moves swung billions of dollars in projected 2028 payment and sent two insurer stocks in opposite directions on the same day.
CMS star ratings fact sheets, 2024-2027
| Value (stars) | Average overall rating |
|---|---|
| 2024 | 4.1 stars |
| 2025 | 4.0 stars |
| 2026 | 4.0 stars |
| 2027 | 4.0 stars |
What CMS actually released for 2027
About 37% of MA-PD contracts, or 188 of 508, earned four or more stars. But 71% of MA-PD enrollees sit in four-plus-star plans, a gap that captures the structural story of this program: enrollment concentrates inside a small number of very large contracts, so contract-level counts and member-level outcomes tell different stories.
The top of the distribution thinned. Only 15 contracts earned five stars for 2027, down from 22 for 2026 and 38 for 2024. The largest single cohort was 3.5 stars, with 164 contracts, or 32.3% of the field. Nonprofit plans again outperformed, with roughly 44% hitting four-plus stars versus 34% of for-profit contracts. Standalone Part D moved sharply the other way: 22% of PDP enrollees landed in four-plus-star contracts for 2027, compared with 2% for 2026.
None of this arrived unannounced. Healthcare Dive reported in September that CMS had raised roughly half of the 2027 cut points in the draft preview, meaning plans knew the grading curve had steepened before the final scores posted.
A half-star is a rounding artifact in a report card. In a bid, it reprices an entire plan year.
Two contracts, two very different 2028s
Humana's largest contract, H5216, covering roughly 2.4 million members, moved from 3.5 to 4 stars. That single change lifted the insurer's share of members in four-plus-star plans to roughly 93-95%, up from the low 20s, a swing Healthcare Dive reported could be worth $3 billion or more in 2028 revenue. Shares rose roughly 13-16% on the news.
Alignment Healthcare ran the same math in reverse. Its California HMO contract H3815 fell from 4 to 3.5 stars. That contract carried roughly 75-81% of plan membership. The stock dropped about 20-23%, and the company said publicly that the rating does not reflect its longstanding performance.
The lesson for boards is not about either company. It is that a plan whose membership sits inside one or two contracts has converted a quality program into a single point of financial failure. A half-star is a rounding artifact in a report card. In a bid, it reprices rebate capacity, supplemental benefit design and competitive positioning for an entire plan year.
The four-year trend line behind the headline
Taken alone, 3.99 versus 4.01 looks like noise. Across four cycles it looks like compression. The enrollment-weighted average ran 4.07 for 2024, dropped to 3.95 for 2025, recovered to 4.01 for 2026 and settled at 3.99 for 2027. Five-star contracts followed a sharper path, from 38 to 9 to 22 to 15.
That volatility is the planning problem. Finance teams cannot treat bonus revenue as a stable base when cut points move annually and the measure set keeps shifting weight toward member experience and administrative measures. Multi-year capital plans built on assumed four-star status are exposed in a way that is easy to miss until the October release.
Why provider executives should care before 2027 contracting
Most of the data that produces a star rating is generated inside hospitals and medical groups. Readmissions, medication adherence, HEDIS gap closure and CAHPS experience scores come out of clinical operations, pharmacy workflows and front-desk interactions, not out of a payer's actuarial department.
Plans that lose bonus dollars will look for that performance somewhere. Expect tighter quality incentive structures, more aggressive risk-sharing terms and sharper data-sharing demands in 2027 network negotiations, particularly from plans with concentrated contract exposure. Provider systems that can document measure-level performance will negotiate from a different position than those that cannot.
For CIOs and CMOs, the practical implication is budgetary. Quality data pipelines, gap-closure tooling and member experience measurement should be scoped as revenue infrastructure with named owners and service levels, not as reporting overhead managed on a best-effort basis.
What payer leaders should pressure-test now
Three questions are worth answering before bid season. First, what share of membership sits in the single largest contract, and what does a half-star move in either direction do to 2028 rebate dollars? That number belongs in front of the board, not buried in an actuarial appendix.
Second, where is the contract sitting relative to cut points on its weakest measures, and how much of that gap is controllable inside twelve months? Measures tied to member experience and pharmacy adherence move on different timelines than clinical quality measures.
Third, does contract consolidation or segmentation strategy need revisiting? Concentration delivers administrative efficiency and, when ratings go up, outsized gain. It also removes the portfolio effect that cushions a single bad year. That tradeoff is now a strategic decision, not an operational one.
